The human papillomavirus (HPV) remains a significant public health concern in Colombia, with recent data from Profamilia revealing a continued high prevalence of the infection. Over 62,000 tests conducted in the last year underscore both the widespread circulation of HPV and the critical need to strengthen vaccination and early detection strategies. This highlights the importance of proactive health measures to combat the spread of this common sexually transmitted infection and prevent its potential long-term consequences, including several cancers.
HPV is often a “silent” infection, meaning most people carrying the virus experience no immediate symptoms. This lack of visible signs makes detection reliant on specialized testing, emphasizing the importance of informed decisions regarding vaccination and regular medical check-ups. Understanding the risks and available preventative measures is crucial for individuals and public health officials alike. You can learn more about common myths surrounding HPV here.
The Pervasive Nature of HPV and Cancer Risk
According to the World Health Organization (WHO), most sexually active individuals will contract HPV at some point in their lives. The WHO estimates that HPV is responsible for approximately 5% of all cancers globally. Often, this infection goes unnoticed, increasing the risk of transmission and the development of long-term complications. HPV isn’t a single virus, but a group of over 200 related types. While some types cause genital warts, others are classified as high-risk and are linked to various cancers, most notably cervical cancer.
Cervical cancer remains a major health risk for women in Colombia, and globally, if left undetected. Early detection through regular screenings is paramount. The challenge lies in the asymptomatic nature of the infection; many individuals are unaware they are infected until tests like Pap smears or HPV DNA tests reveal its presence. This underscores the necessity of routine medical examinations for preventative care.
Profamilia’s “Primero Tú” Program and Recent Findings
Recognizing the ongoing need for improved prevention and detection, Profamilia launched the “¡Primero Tú! Prevención de Cáncer de Cuello Uterino” (First You! Cervical Cancer Prevention) program in 2025. This initiative aims to expand access to early detection services and promote self-care practices. The program focuses on bringing preventative tools to more people and strengthening education around sexual and reproductive health.
Tatiana Gómez, a scientific advisor at Profamilia, emphasizes the importance of clear information. “When people have access to tools like vaccination and diagnostic tests, they can make timely decisions that significantly reduce the risk of developing cancer,” she stated. Recent results from Profamilia demonstrate progress in these efforts. In the past year, over 62,000 HPV DNA tests were performed, identifying more than 9,000 positive cases with appropriate follow-up care. 45,701 Pap smears were conducted, with 90% returning normal results, 15,502 cervical biopsies were performed, and 13,115 HPV vaccinations were administered.
Vaccination and Prevention Strategies
Vaccination remains the most effective tool in preventing HPV infection. The HPV vaccine is highly effective, particularly when administered before the onset of sexual activity. The vaccine protects against the types of HPV most commonly associated with genital warts and cervical cancer. Beyond vaccination, consistent condom use and regular medical check-ups are also vital components of a comprehensive prevention strategy.
The Colombian Ministry of Health and Social Protection recommends HPV vaccination for girls and boys aged 9-17, as part of the National Immunization Program. You can find more information about the national vaccination schedule on the Ministry’s website. Still, access to vaccination can vary depending on geographic location and socioeconomic factors, highlighting the need for continued efforts to ensure equitable distribution.
Understanding the Different Types of HPV
It’s important to understand that HPV is not a single entity. There are over 200 types, categorized by their risk level. Some types cause benign conditions like common warts, while others are considered high-risk due to their association with cancer. The most common high-risk types are HPV 16 and HPV 18, responsible for approximately 70% of cervical cancer cases worldwide.
Regular screenings, such as Pap smears and HPV DNA tests, can detect these high-risk types even before cellular changes occur, allowing for early intervention and treatment. The frequency of screenings is typically recommended every three to five years, depending on individual risk factors and medical history.
As part of the commemorations in March, including International HPV Awareness Day and World Cervical Cancer Day, Profamilia continues to promote prevention campaigns, including discounts on the vaccine and expanded access to diagnostic testing in various regions of the country. These efforts aim to reduce the impact of a disease that, with information and care, is largely preventable.
Disclaimer: This article provides general health information and should not be considered medical advice. Please consult with a qualified healthcare professional for personalized guidance and treatment.
The ongoing efforts to combat HPV in Colombia represent a crucial step towards improving public health and reducing the incidence of cervical cancer. Profamilia will continue to analyze data from the “¡Primero Tú!” program throughout 2024, with a comprehensive report expected in early 2025 detailing the program’s impact and outlining future strategies. Share this information with your network and join the conversation about HPV prevention.
